Artificial intelligence predicts radiation tx side effects for pts with head & neck cancers

September 26, 2019

For the first time, a sophisticated computer model has been shown to accurately predict two of the most challenging side effects associated with radiation therapy for head and neck cancer. This precision oncology approach has the potential to better identify patients who might benefit from early interventions that may help to prevent significant weight loss after treatment or reduce the need for feeding tube placement. Findings were presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

"In the past, it has been hard to predict which patients might experience these side effects," said Jay Reddy, MD, PhD, an assistant professor of radiation oncology at The University of Texas MD Anderson Cancer Center and lead author on the study. "Now we have a reliable machine learning model, using a high volume of internal institutional data, that allows us to do so."

Machine learning is a branch of artificial intelligence that uses statistical models to analyze large quantities of data, uncovering patterns that can predict outcomes with a high degree of accuracy. Used by the tech industry to allow speech and facial recognition, "spam" filtering and targeted advertising, machine learning has been an emerging topic of interest for medical researchers seeking to translate large amounts of data into knowledge that can support clinical decision making.

Dr. Reddy and his team developed models to analyze large sets of data merged from three sources: electronic health records (Epic), an internal web-based charting tool (Brocade) and the record/verify system (Mosaiq). The data included more than 700 clinical and treatment variables for patients with head and neck cancer (75% male/25% female, with a median age of 62 years) who received more than 2,000 courses of radiation therapy (median dose 60 Gy) across five practice sites at MD Anderson from 2016 to 2018.

Researchers used the models to predict three endpoints: significant weight loss, feeding tube placement and unplanned hospitalizations. Results from the best-performing model were then validated against 225 subsequent consecutive radiation therapy treatments. Models with a performance rate that met a pre-specified threshold of area under the curve (AUC) of 0.70 or higher were considered clinically valid. (An AUC score of 1.0 would mean the model's predictions were 100% accurate, while a score of 0.0 would mean the predictions were never accurate.)

Approximately 53,000 people are diagnosed with head and neck (oral cavity or oropharyngeal) cancers each year in the United States. These cancers are more than twice as common in men as in women, and typically diagnosed later in life (with an average age of diagnosis of 62 years). Head and neck cancers, when diagnosed early, are typically treated with radiation therapy or surgery. Later-stage cancers are treated with a combination of radiation therapy and chemotherapy. A patient may also be treated first with surgery, followed by radiation therapy alone or by a combination of radiation and chemotherapy.

Radiation therapy is effective at treating head and neck cancer by slowing or stopping the growth of new cancer cells. However, it may also damage oral tissue and upset the balance of bacteria in the mouth, causing adverse side effects such as a sore throat, mouth sores, loss of taste and dry mouth. When sore throats are severe, they can make it difficult for the patient to eat and may lead to weight loss or require the temporary insertion of a feeding tube. Nearly all patients with head and neck cancer experience some negative effects of treatment.

"Being able to identify which patients are at greatest risk would allow radiation oncologists to take steps to prevent or mitigate these possible side effects," said Dr. Reddy. "If the patient has an intermediate risk, and they might get through treatment without needing a feeding tube, we could take precautions such as setting them up with a nutritionist and providing them with nutritional supplements. If we know their risk for feeding tube placement is extremely high - a better than 50% chance they would need one - we could place it ahead of time so they wouldn't have to be admitted to the hospital after treatment. We'd know to keep a closer eye on that patient."

The models predicted the likelihood of significant weight loss (AUC = 0.751) and need for feeding tube placement (AUC = 0.755) with a high degree of accuracy.

"The models used in this study were consistently good at predicting those two outcomes," said Dr. Reddy. "You could rerun those models with a new patient or series of patients and get a number saying this adverse effect is likely to happen or not to happen."

For example, said Dr. Reddy, using their model, clinicians could potentially plug in information related to a specific patient - such as age, gender, type of cancer and other distinct variables - and the model might tell them, "Eighty percent of people like you with this clinical profile get through treatment without a feeding tube. It may not be perfect, but it's better than having no understanding at all."

The model fell short of predicting unplanned hospitalizations with sufficient clinical validity (AUC = 0.64). Redoing the analyses with more "training" data for unplanned hospitalizations could improve accuracy in predicting this side effect as well, said Dr. Reddy. "As we treat more and more patients, the sample size gets bigger, so every data point should get better. It's possible we just didn't have enough information accumulated for this aspect of the model."

While the machine learning approach can't isolate the single-most predictive factor or combination of factors that lead to negative side effects, it can provide patients and their clinicians with a better understanding of what to expect during the course of treatment, said Dr. Reddy. In addition to predicting the likelihood of side effects, machine learning models could potentially predict which treatment plans would be most effective for different types of patients and allow for more personalized approaches to radiation oncology, he explained.

"Machine learning can make doctors more efficient and treatment safer by reducing the risk of error," said Dr. Reddy. "It has the potential for influencing all aspects of radiation oncology today - anything where a computer can look at data and recognize a pattern."
The abstract, "Applying a machine learning approach to predict acute radiation toxicities for head and neck cancer patients," was presented in detail at ASTRO's 61st Annual Meeting in Chicago. Audio and slides from the news briefing are available at To schedule an interview with Dr. Reddy and/or outside experts, contact ASTRO's media relations team at


The American Society for Radiation Oncology (ASTRO) is the world's largest radiation oncology society , with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. The Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology * Biology * Physics, Practical Radiation Oncology and Advances in Radiation Oncology; developed and maintains an extensive patient website, RT Answers; and created the nonprofit foundation Radiation Oncology Institute. To learn more about ASTRO, visit

American Society for Radiation Oncology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to